Cormorant Asset Management’s HTG Molecular Diagnostics, Inc. Common Stock HTGM Stock Holding History

Cormorant Asset Management’s Portfolio HTGM Stock Details HTGM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-1,130	Closed	-$541K	–	70
2017 Q2	$541K	Hold	1,130	–	–	0.09%	65
2017 Q1	$1.41M	Hold	1,130	–	–	0.2%	66
2016 Q4	$456K	Hold	1,130	–	–	0.06%	70
2016 Q3	$472K	Hold	1,130	–	–	0.05%	75
2016 Q2	$529K	Buy	1,130 +13	+1%	+$6.6K	0.08%	74
2016 Q1	$577K	Hold	1,117	–	–	0.09%	75
2015 Q4	$876K	Hold	1,117	–	–	0.1%	70
2015 Q3	$1.53M	Hold	1,117	–	–	0.24%	67
2015 Q2	$2.24M	Buy	+1,117	New	+$2.85M	0.3%	60

Other funds holding HTGM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Cormorant Asset Management's HTGM Position: Q3 2017 in Review

Cormorant Asset Management sold out of HTG Molecular Diagnostics, Inc. Common Stock (HTGM) in Q3 2017, closing a stake of 1,130 shares — an estimated $541K sold.

Cormorant Asset Management first reported a position in HTGM in Q2 2015 and held it in 9 quarters. The position peaked at $2.24M in Q2 2015. 21 funds tracked by Wall St. Rank hold HTGM as of Q3 2017.

Cormorant Asset Management reported no remaining HTG Molecular Diagnostics, Inc. Common Stock position as of Q3 2017 after selling out during the quarter.
Cormorant Asset Management sold 1,130 HTG Molecular Diagnostics, Inc. Common Stock shares in Q3 2017, an estimated $541K.
Cormorant Asset Management first reported a position in HTG Molecular Diagnostics, Inc. Common Stock in Q2 2015 and held it in 9 quarters.
Cormorant Asset Management's HTG Molecular Diagnostics, Inc. Common Stock position peaked at $2.24M in Q2 2015.
21 funds tracked by Wall St. Rank held HTG Molecular Diagnostics, Inc. Common Stock as of Q3 2017.

Based on Cormorant Asset Management's 13F filing for Q3 2017, filed 14 Nov 2017.